RESUMO
Our investigation of immune and cytokine status in patients with chronic prostatitis shows that basic treatment neither normalizes nor improves life quality in patients with chronic prostatitis. The addition of azoximer injections to basic treatment of chronic prostatitis improves or normalizes the majority of abnormal parameters of immune and cytokine status except neutrophil phagocyte activity, IL-1beta concentration in the blood serum, IL-6 and IL-1beta concentration in prostatic gland secretion. Chronic prostatitis treatment with azoximer injections in combination with LRS has positive immunological and clinical effects.
Assuntos
Interleucina-1beta/imunologia , Interleucina-6/imunologia , Neutrófilos/imunologia , Fagocitose/imunologia , Prostatite/imunologia , Adulto , Doença Crônica , Humanos , Interleucina-1beta/sangue , Interleucina-6/sangue , Masculino , Pessoa de Meia-Idade , Prostatite/sangue , Prostatite/tratamento farmacológico , Qualidade de VidaRESUMO
Our investigations demonstrate high antioxidant and immunomodulating activity of prostamol-uno in benign prostatic hyperplasia and chronic prostatitis. This gives grounds for using this drug not only in benign prostatic hyperplasia but also in chronic prostatitis.